Edwards Lifesciences Corporation Edwards Lifesciences Corporation

Edwards Lifesciences Corporation

EW

Peringkat dalam Saham #478
Edwards Lifesciences Corporation is a global medical technology firm... Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Harga Saham
$88.23
Terakhir disinkronkan: 2026-10-20
Kapitalisasi Pasar
$50.86B
Perubahan (1 hari)
1.08%
Perubahan (1 tahun)
16.06%
Negara
US
Perdagangan Edwards Lifesciences Corporation (EW)

Kategori

Healthcare
Pendapatan untuk Edwards Lifesciences Corporation (EW)
Pendapatan pada Jun 2026 TTM: $6.51B
Menurut laporan keuangan terbaru dari Edwards Lifesciences Corporation, pendapatan saat ini (TTM) adalah $6.51B. Pada tahun 2024, perusahaan menghasilkan pendapatan sebesar $5.44B peningkatan dibandingkan pendapatan pada tahun 2023 yang sebesar $5.01B. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Edwards Lifesciences Corporation dari 2000 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Mengubah
2026 (TTM) $6.51B 7.33%
2025 $6.07B 11.55%
2024 $5.44B 8.57%
2023 $5.01B -6.92%
2022 $5.38B 2.86%
2021 $5.23B 19.29%
2020 $4.39B 0.88%
2019 $4.35B 16.79%
2018 $3.72B 8.37%
2017 $3.44B 15.91%
2016 $2.96B 18.85%
2015 $2.49B 7.35%
2014 $2.32B 13.56%
2013 $2.05B 7.68%
2012 $1.90B 13.17%
2011 $1.68B 16.01%
2010 $1.45B 9.51%
2009 $1.32B 6.76%
2008 $1.24B 13.44%
2007 $1.09B 5.22%
2006 $1.04B 3.92%
2005 $997.90M 7.13%
2004 $931.50M 8.25%
2003 $860.50M 22.23%
2002 $704.00M 1.73%
2001 $692.00M -13.93%
2000 $804.00M 0.00%
Pendapatan untuk perusahaan serupa atau pesaing
Perusahaan Pendapatan Perbedaan Pendapatan Negara
$46.59B 615.34%
US
$35.48B 444.88%
IE
$25.84B 296.74%
US
$21.00B 222.41%
US
- -
DE